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In cystic fibrosis, colonization of the airways with Pseudomonas aeruginosa followscoloni-
zation with Staphylococcus aureus and is related to accelerated deterioration of pulmonary
function. Because P. aeruginosa adheres better to cell surfaces devoid of fibronectin, we
searched for fibronectin-cleaving activity in bronchial secretions and saliva from 24 pa-
tients with cystic fibrosis who were followed up for 4.5 y and from two control groups.
Proteolytic activity against 12sI-labeled fibronectin wascontinuously present in cysticfibrosis
bronchial secretions; significantly higher fibronectin-cleaving activity was found in older
vs. younger patients, in patients with advanced disease stages determined by a five-stage
scoring system, and in those colonized with P. aeruginosa. The fibronectin-cleaving ac-
tivity was due to neutrophil elastase and cathepsin G. Cystic fibrosis bronchial secretions
had proteolytic activity against surface fibronectin of airway mucosal cells. Thus fibro-
nectin-cleavingactivity of bronchial secretions rather than of saliva may favor P. aeruginosa
colonization of the upper respiratory tract in individuals with cystic fibrosis.
Most individuals with cystic fibrosis who survive be-
yond the neonatal period die from respiratory fail-
ure, which is the consequence of chronic, pro-
gressively destructive bronchitis [1-3]. Clinical and
pathological observations show extensive tissue de-
struction in the airways, which first causes obstruc-
tion and obliteration of small airways and thereafter
destruction of the walls of large airways [4, 5]. Early
in the disease course the bacterial pathogens fre-
quently found in the bronchial secretions are Staph-
ylococcus aureus and Haemophilus influenzae. Later
the airways of these subjects are invariably colonized
with Pseudomonas aeruginosa, an event that initi-
ates an acclerated deterioration of lung functions [3]
as wellas an excessive systemic immune response [6].
These pathogens cannot be eliminated from the air-
ways by antimicrobial therapy, and because the del-
eterious effect of P. aeruginosa infection in individ-
uals with cystic fibrosis is well established, the
identification of factors favoring colonization of the
airways with P. aeruginosa is important. Coloniza-
Received for publication 29 October 1987and in revised form
27 January 1988.
This work was supported by grants 3.816-0.84 and 3.850-0.86
from the Swiss National Research Foundation.
Wethank Dr. A. Baici for suggestions and P. Schilling for manu-
script preparation.
Please address requests for reprints to Dr. Susanne Suter, Cli-
nique Universitaire de Pediatrie, 30, bd de la Cluse, 1211 Geneva
4, Switzerland.
89
tion of the upper respiratory tract with bacterial
pathogens is achieved by binding of bacteria to epi-
thelial cell surfaces. Severalexperimental studies have
shown that the type of bacteria binding to epithelial
surfaces is influenced by the presence of fibronec-
tin, a glycoprotein on the cell surface [7-11]. The ab-
sence of fibronectin on epithelial cell surfaces from
patients with cystic fibrosis [9] as well as from seri-
ously ill patients with acute respiratory failure [10]
correlated with increased adherence of P. aeruginosa
to buccal epithelial cells. In these studies a parallel
increase in activity of salivary proteases was demon-
strated, and it was suggested that salivary proteases
were the source of fibronectin-cleaving activity in
these patients. However, in individuals with cystic
fibrosis, not only saliva but also bronchial secretions
may be the source of proteolytic activity [11-13].
Wetherefore attempted to quantitate and identify
the fibronectin-cleaving enzymes in cystic fibrosis
bronchial secretions and saliva in comparison with
those from a control group of patients with chronic
bronchitis. We also determined the proteolytic ef-
fect of cystic fibrosis bronchial secretions on cell sur-
face fibronectin of airway mucosal cells of human
lung tissue.
Patients and Methods
Study group. Twenty-four patients with cystic
fibrosis attending the cystic fibrosis clinic or hospital-
ized at the Children's Hospitals of the Universities
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of Bern (Switzerland) and Geneva wereprospectively
included in the study since 1982. The diagnosis of
cystic fibrosis had been established by clinical fea-
tures of the disease and was confirmed by sweat con-
centrations of Na" and Cl of >70 mEq/L. The mean
age of the patients was 12.7y (range, 15mo to 21 y),
Cultures of sputum from nine patients werepositive
mainly for S. aureus; other pathogens isolated in-
cluded H. influenzae, ~-hemolytic Streptococcus
group A, and Escherichia coli. The mean age of these
patients was 8.1 y (range, 15mo to 15y). Fifteen pa-
tients had cultures of sputum positive for P. aerugi-
nosa; other pathogens isolated from these patients
were S. aureus and Aspergillusfumigatus. The mean
age of this group was 15.5 y (range, 5.5-20 y). All
patients who were colonized with P. aeruginosa were
hospitalized three times per year for iv antimicrobial
therapy.
Clinical and radiographic staging of cystic fibro-
sis was done by one of us, unaware of the labora-
tory results, with use of a five-stage scoring system
[14], based on physical activity, general physical con-
dition and bacteriology of sputum, signs of pulmo-
nary disease, radiological lung involvement, and gas-
trointestinal manifestations. Each parameter was
assigned a maximum of 5 points, with the highest
score indicating the best status. Severity of the dis-
ease was graded in five stages (I-V). Radiographic
scoring was done with the scoring system of Chrispin
and Norman [15]. The highest stage (V) corresponds
to poor pulmonary condition and advanced radio-
graphic alterations of cystic fibrosis.
Control groups. Two control groups were also
included in the study: one group included 16patients
with acute exacerbations of chronic bronchitis and
bronchiectases, as documented by chronic cough,
purulent sputum, positive chest findings, and roent-
genograms. In nine patients, bronchiectases had been
documented by bronchography or bronchoscopy.
The mean age of the patients was 45 y (range, 9-
56 y). Pathogens isolated from sputum included
H. influenzae, Streptococcus pneumoniae, E. coli,
S. aureus, and Aspergillus. The second control group
included 10 patients who had chronic bronchitis
without acute exacerbation (all of whom were
smokers), as documented by chronic cough and in-
creased amounts of nonpurulent sputum. These pa-
tients produced sputum that was negative when cul-
tured for bacterial pathogens. The mean age of these
patients was 68 y (range, 41-90 y).
Specimens. From all these patients, bronchial
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secretions were collected according to the following
protocol: Fresh morning sputum was obtained dur-
ing morning chest physiotherapy. For the patients
with cystic fibrosis the number of samples collected
per patient ranged from four to 22 over a period of
4.5 y. From two patients with cystic fibrosis and six
patients with chronic bronchitis a sample of morn-
ing sputum and a sample obtained by bronchosco-
py were collected on the same day. None of the pa-
tients received mucolytic treatment during the study
period.
Cultures and identifications of bacteria from
bronchial secretions were done according to well-
established methods [16]. The secretions were mixed
with a half volume of sterile 0.9070 NaCI and shaken
by hand for 1min; the mixture was then centrifuged
at 1000g until the supernatant was clear. The super-
natants were stored at - 70 C until tested, and the
total protein concentration was determined by a stan-
dard method (Biorad, Richmond, Calif). Ten bron-
chial secretions had been subjected to ultracentrifu-
gation at 30000 g for 30 min without prior dilution,
and the enzymatic activities were measured in these
supernatants.
We also collected saliva from 18 healthy individ-
uals and from 14 patients with cystic fibrosis (11
colonized with P. aeruginosa and three not colonized
with P. aeruginosa); these samples were centrifuged
without prior dilution. The saliva of patients with
cystic fibrosis was obtained during a cough-free
period after chest physiotherapy, and only saliva that
was macroscopically free from bronchial secretions
was examined. No stimulus was used for stimulat-
ing production of saliva.
Lung tissue wasobtained at autopsy from an eight-
month-old child without cystic fibrosis and without
lung disease.
Three strains of P. aeruginosa, isolated from our
patients with cystic fibrosis, that secreted bacterial
elastase [11] were cultured in Mueller-Hinton broth
for 24 h; the culture supernatant was obtained by
centrifugation at 8000 g for 20 min.
Assessment oj fibronectin-cleaving activity oj
bronchial secretions and saliva. Fibronectin was
purified from human plasma [17] and radiolabeled
with 1251 [18] (Amersham Corp., Amersham, En-
gland). About 250000 cpm of 1251was incorporated
into 1 ug of purified fibronectin. 125I-Labeled fibro-
nectin C251-fibronectin) was then coupled with
CNBr-activated Sepharose" 4B (Pharmacia Fine
Chemicals, Uppsala, Sweden). 1251-Fibronectin-
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Sepharose beads corresponding to 250 000 cpm were
then suspended in 500 ul, of Dulbecco's PBS (pH
7.4) and incubated at 37 C with 10 ul, of bronchial
secretion, saliva, or purified neutrophil enzymes for
4 h. 1251-Fibronectin fragments were separated from
1251-fibronectin still bound to Sepharose by centrifu-
gation at 8000 g for 5 min. Proteolysis of fibronec-
tin was expressed as a percentage of the cpm in the
supernatant divided by the cpm of the total sample.
Spontaneous release of 125 1 from fibronectin was
measured simultaneously «2010) and subtracted
from the results. The time course of degradation of
1251-fibronectin by bronchial secretions and by puri-
fied neutrophil enzymes was similar and showed that
the enzymatic reaction was not linear; 1251_fibronectin
fragments were rapidly released over the first min-
ute of incubation, followed by slower release over
a 4-h period.
For characterizing the fibronectin fragments
generated by bronchial secretions, the fragments pro-
duced by proteolysis of purified (unlabeled) fibro-
nectin by a pool of cystic fibrosis bronchial secre-
tions over time was compared with the fragments
generated by a mixture of purified elastase (three
parts) and cathepsin G (one part). The fragments
were separated with PAGE [19]. After electrophore-
sis the gels were incubated in 25 mM Tris and 20%
methanol (pH 10.4)for 15min, and the proteins were
transferred to Novilon" membranes (Millipore Corp.,
Bedford, Mass) by using a Multiphor II Novablot"
system (LKB, Bromma, Sweden) at 150 rnA for 90
min [20]. The membrane was then slowly shaken in
a blocking buffer (10 mM Tris, 1 mM EDTA, 133
mMNaCI, 10010 skim milk, 0.05% Triton X-l00, and
2% sodium azide) at room temperature (1'\.123 C) for
2 h. Subsequently the membrane was incubated in
skim milk (Difco, Detroit) containing an antibody
to fibronectin raised in rabbits (Behring, Marburg,
Federal Republic of Germany) at a dilution of 1:4000
followed by three washing steps in PBS (pH 7.4), Ca"
and Mg" free. During the next step the Novilon
membrane was incubated in skim milk containing
an antibody to rabbit IgG bound to alkaline phos-
phatase (Sigma, St. Louis) at a dilution of 1:2000
for 2 h. After three washing steps in Ca"- and Mg"-
free PBS, the membrane was incubated in 50 mM
Tris (pH 8) for 10 min and exposed to the chromo-
genic substrate (naphthol AS-MX [40 mg] and fast
red salt [80 mg; both from Sigma] in 50 mM Tris).
The reaction was stopped by washing the Novilon
membrane in tap water for 10min. Molecular weights
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were monitored with standard proteins (Biorad),
which were revealed with amido-black staining.
Zymographs. To identify fibronectin-cleaving
enzymes in cystic fibrosis bronchial secretions, we
modified previously published methods [21, 22] for
zymographs. Purified fibronectin (1.5 mg/mL) was
added to a 7.5% (wt/vol) polyacrylamide gel before
polymerization. The stacking gel contained no fi-
bronectin. One microliter of a pool of cystic fibro-
sis bronchial secretions, purified elastase, cathepsin
G, or a mixture (3:1)of purified elastase and cathep-
sin G was added to 9 ul, of sample buffer [21] and
electrophoresed through the fibronectin-containing
gel at 4 C for 5 h at 170 V without prior heating of
the samples. SDS was then removed from the gel by
incubation of the gel in 2.5% Triton X-100 for 1 h.
Thereafter the gel was incubated at 37 C for 16 h
in 0.1 M glycine, pH 8.3, 7.4, or 6.8. Proteins were
transferred to Novilon membranes, and fibronectin
was revealed as described above. With this procedure
the location to which a fibronectin-degrading pro-
tease had migrated was seen as a clear band, in which
copolymerized fibronectin had been degraded. In
control experiments, samples heated to 90 C for 15
min weretested, and in others the Novilon membrane
was incubated in 2 mM phenylmethylsulfonyl fluo-
ride (PMSF) dissolved in methanol for 1 h before
incubation with the antibodies.
Determination ofelastolytic activityofbronchial
secretions. The elastolytic activity was determined
as described by Hornebeck and Schnebli [23] with
purified bovine elastin (Sigma) radioactively labeled
with 3H (New England Nuclear Corp., Boston). Ten
microliters of the bronchial secretion was incubated
with 500 ug of 3H-Iabeled elastin suspended in 1 mL
of 0.1 M Tris(pH 8.2)containing 0.01% 23 lauryl ether
(Brij" 35; Sigma) and 0.02% sodium azide for 16 h
at 37 C. The samples were centrifuged at 3300 g for
10min. The radioactivity of 100 ul, of the superna-
tant was then measured and used for calculating the
amount of solubilized elastin. One milligram of com-
pletely solubilized 3H-Iabeled elastin corresponded
to 145 000 cpm. Elastolytic activity (DE) was ex-
pressed as the number of milligrams of labeled
elastin solubilized by 1 mL of enzyme solution. This
enzymatic reaction was linear over the interval tested.
Purified human neutrophil elastase [24] and ca-
thepsin G [25] were used as controls. For determin-
ing the concentration of inhibitors that achieved
complete inhibition of purified leukocyte elastase
and cathepsin G, the activity of these enzymes was
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measured with the synthetic substrates Succ-Ala-
Ala-Pro-Val-pNA and Succ-Ala-Pro-Phe-pNA (both
from Calbiochem Behring, Luzern, Switzerland)
[26].
- Inhibition experiments. The 1251-fibronectin-
cleaving activity of cystic fibrosis bronchial secre-
tions was also determined after prior incubation of
bronchial secretions with the following inhibitors:
partially purified aI-proteinase inhibitor (arPI;
Sigma); PMSF (Sigma); Eglin C, an inhibitor of neu-
trophil elastase and cathespin G [27]; Ac-Ala-Ala-
Pro-Val-ChCI2 [26], a specific inhibitor of neutro-
phil elastase; Ac-Ala-Ala-Pro-Phe-ChCl., a specific
inhibitor of cathepsin G [26] (both peptides from
Enzyme Systems Products, Livermore, Calif); and
o-phenanthroline (Sigma), an inhibitor of metal-
loproteases such as pseudomonas elastase [28]. We
also inactivated the proteolytic activity of cystic
fibrosis bronchial secretions by heating at different
temperatures.
Assessment of proteolysis of cellular fibronec-
tin. Because plasma fibronectin and cellular fibro-
nectin have different subunit structures [29], we stud-
ied the proteolytic effect of cystic fibrosis bronchial
secretions on cellular fibronectin of airway mucosa.
Cellular fibronectin was revealed by direct immuno-
fluorescence with an FITC-conjugated [30] antibody
to fibronectin that had been raised in rabbits. Sec-
tions of frozen lung tissue 4 urn thick were fixed on
glass slides coated with poly-t-lysine (Sigma) by ex-
posure to acetone for 2 min. The preparation was
rinsed three times with PBS, and a drop of FITC-
conjugated antiserum to fibronectin was deposited
on the tissue section. Fluorescence was observed in
a fluorescent light microscope after incubation for
30 min with the antibody, subsequent rinsing with
PBS, and exposure to 90010 glycerol [31]. Immuno-
fluorescent fibronectin was observed after incuba-
tion of lung tissue sections with cystic fibrosis bron-
chial secretions. No fluorescence was observed when
the antibody to fibronectin was adsorbed with puri-
fied fibronectin before incubation with the lung tis-
sue. Quenching of fluorescence by bronchial secre-
tions was excluded by an experiment in which the
cystic fibrosis bronchial secretion had been incubated
with an excess amount of Eglin C (100 !lM) before
incubation with lung tissue sections.
Statistical analysis. Results are given as mean
± SD values. Comparisons were made with the
Mann-Whitney test, and correlations were analyzed
with the Spearman correlation coefficient.
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Results
Elastolytic and 125I-fibronectin-cleaving activities
and protein concentration of bronchial secretions
and saliva. Bronchial secretions from patients with
cystic fibrosis and patients with acute exacerbations
of chronic bronchitis had a significantly higher mean
fibronectin-cleaving activity than did bronchial se-
cretions from patients with chronic bronchitis with-
out acute exacerbation (P< .01) and than did saliva
from patients with cystic fibrosis (P < .01) and nor-
mal individuals (P < .01; table 1). Saliva from pa-
tients with cystic fibrosis had significantly higher
mean fibronectin-cleaving activity than that from
normal individuals (P < .01).
The elastolytic activity of cystic fibrosis bronchial
secretions (1.61 ± 0.85 UE) was significantly higher
than the elastolytic activity of bronchial secretions
from patients with chronic bronchitis and acute
exacerbation (0.42 ± 0.33 UE)' No measureable
elastolytic activity was found in bronchial secretions
from those with chronic bronchitis without acute ex-
acerbation and in saliva from patients with cystic
fibrosis and normal individuals. The elastolytic ac-
tivity of the bronchial secretions obtained by bron-
choscopy of two patients with cystic fibrosis and six
patients with chronic bronchitis correlated well with
that of the morning sputum sample of the same day,
and no significant differences were observed in sam-
ples of bronchial secretions diluted with 0.9% NaCI
and shaken by hand before centrifugation and those
prepared by ultracentrifugation starting from the
same sample. Because the precise quantitation of leu-
kocytes in bronchial secretions is not feasible owing
to the viscosity of the samples and because our previ-
ous studies had shown a good correlation between
semiquantitative determination of leukocyte counts
and elastolytic activity of bronchial secretions [11,
12], we made no attempt to quantitate neutrophils
in the secretions.
None of the culture supernatants of the three
elastase-producing strains of P. aeruginosa had sig-
nificant 1251-fibronectin-cleaving activity.
The total protein concentration was significantly
higher in bronchial secretions from patients with cys-
tic fibrosis and those with chronic bronchitis with
acute exacerbations than in the bronchial secretions
from those with chronic bronchitis without acute ex-
acerbation and in the samples of saliva from patients
with cystic fibrosis and normal individuals (P< .01).
The mean protein concentration of cystic fibrosis
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Table 1. Elastolytic and fibronectin-cleaving activities and protein concentration of bronchial secretions and saliva.
No. tested
Elastolytic Fibronectin-cleaving Total protein
Specimen, group Patients Samples activity (VE) activity (070) concentration (g/L)
Bronchial secretions
Cystic fibrosis 24 194 1.61 ± 0.85* 39.1 ± 15.2 5.8 ± 3.8
Chronic bronchitis
With acute exacerbations 16 24 0.42 ± 0.33*t 37.5 ± 16.2t 4.0 ± 3.6
Without acute exacerbations 10 12 <0.05t 3.3 ± 3.4t 2.4 ± 2.7
Saliva
Cystic fibrosis 14 24 <0.05 8.2 ± 19.0 2.4 ± 2.1
Normal 18 18 <0.05 4.0 ± 9.0 1.4 ± 0.7
NOTE. Elastolytic activity is mg of 3H-Iabeled elastin solubilized (16 h at 37 C) by I mL of undiluted sample. Fibronectin-
cleaving activity is the percentage of the cpm of 1Z51-fibronectin released in the supernatant divided by the radioactivity of the total
sample. All tests were done in triplicate, and the background (determined by incubation of the substrates without the source of
enzymes) was subtracted. Data are mean ± SD values. For statistical evaluation the Mann-Whitney test was used.
* p < .01.
t p < .01.
t p < .01.
bronchial secretions was significantly higher (P
< .05) than that of bronchial secretions from patients
with chronic bronchitis and acute exacerbations.
Inhibition experiments. The elastolytic activity
of all samples of bronchial secretions was inhibited
86%-95070by 2 mMPMSF, a finding demonstrating
that most of it was due to serine proteases (table 2).
To determine which enzyme(s) might be respon-
sible for the fibronectin-cleaving activity, we used
specific inhibitors of neutrophil elastase, cathepsin
G, or both. The inhibition as a percentage of fibro-
nectin-cleaving activity of cystic fibrosis bronchial
secretions, purified neutrophil elastase, and cathep-
sin G is shown in table 2. Purified lIt-PI, PMSF, and
Eglin C inhibited the fibronectin-cleaving activity
of cystic fibrosis bronchial secretions substantially
(80%-90%) as well as that of purified neutrophil
elastase and cathepsin G, with one exception: As ex-
pected [32], the fibronectin-cleaving activity of puri-
fied cathepsin G was inhibited only 37% by partially
purified lIt-PI at the concentration used. We then
tried to distinguish fibronectin-cleaving activity due
to elastase from that due to cathepsin G by using
the elastase-specific [26] inhibitor Ac-Ala-Ala-Pro-
Table 2. Inhibition of I25I-fibronectin-cleaving activity by various inhibitors and inactivation by heating.
Inhibition (070) of "'I-fibronectin - cleaving activity of
Inhibitor (concentration)
a.-PI (4 ~M)
PMSF (2 mM)
Eglin C (12.5 l!M)
Ac-Ala-Ala-
Pro-Val-ChCI, (I mM)
Ac-Ala-Ala-
Pro-Phe-ChCl, (I mM)
Heating at
60 C for 15 min
80 c for 15 min
Cystic fibrosis Purified Purified
bronchial secretions neutrophil elastase cathepsin G
80 ± 7 (9) 89 ± 3 (4) 37 ± 9 (4)
90 ± 5 (11) 95 ± 2 (7) 91 ± 2 (7)
87 ± 8 (11) 98 ± 3 (7) 99±1(7)
67 ± 9 (10) 82 ± 3 (4) 28 ± 9 (4)
84 ± 9 (9) 89 ± 3 (4) 93 ± 3 (4)
II ± 6 (2) 22 ± 8 (3) 87 ± 3 (3)
96 ± 2 (2) 98 ± I (3) 94 ± 2 (3)
NOTE. Fibronectin-cleaving activity of bronchial secretions and purified neutrophil enzymes was tested simultaneously in the
presence and in the absence of the indicated inhibitors or after heat inactivation of the samples. Inhibition is expressed as 100 x
(activity of the sample with inhibitor/activity of the sample without the inhibitor). Bronchial secretions were preincubated with
the inhibitor for 15 min. Data are mean ± SD values (no. of bronchial secretions tested in triplicate).
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Val-ChCI2 and the cathepsin G-specific inhibitor [26]
Ac-Ala-Ala-Pro-Phe-ChCl.. We first determined the
concentration of inhibitor inhibiting the esterolytic
activity of purified elastase and cathepsin G; the es-
terolytic activity on the specific substrates of both
enzymes was inhibited efficiently (>95070) when the
inhibitor was used at 20 ~M. However, the fibronec-
tin-cleaving activity of purified elastase and cathep-
sin G was not substantially reduced when we used
the inhibitor at this concentration, and we therefore
increased the concentration of inhibitor to 1 mM.
Under these conditions the elastase-specific inhibi-
tor partially inhibited the fibronectin-cleaving activ-
ity of cathepsin G (28%), whereas the cathepsin
G-specific inhibitor also inhibited the fibronec-
tin-cleaving activity of purified elastase by 84%. The
fibronectin-cleaving activity of cystic fibrosis bron-
chial secretions was inhibited 67% by the elastase-
specific and 84% by the cathepsin G-specific inhib-
itor. Because cathepsin G is less resistant to heat than
is elastase [33], we also tested the heat resistance of
the fibronectin-cleaving activity of cystic fibrosis
bronchial secretions and of purified elastase and
cathepsin G. Whereas the fibronectin-cleaving ac-
tivity of purified elastase and the cystic fibrosis bron-
chial secretions was inactivated only after heating
of the samples at 80 C for 15 min, that of purified
cathepsin G was inactivated 87% after heating at
60 C for 15 min.
From these inhibition experiments we concluded
that (1) the fibronectin-cleaving activity of cystic
fibrosis bronchial secretions was inhibited best by
PMSF and Eglin C (90% and 87%, respectively),
which inhibit both cathepsin G and elastase; (2) the
specific chloromethylketone inhibitors of cathepsin
G and elastase did not allow us to distinguish be-
tween these two enzymes as a source of fibronectin-
cleaving activity in cystic fibrosis bronchial secretions
because they lost their specificity at a concentration
of 1mM; and (3) the heat resistance of the fibronec-
tin-cleaving activity of cystic fibrosis bronchial secre-
tions was similar to that of elastase rather than of
cathepsin G. Phenanthroline (l mM), which in-
hibited the elastolytic activity of P. aeruginosa cul-
ture supernatant by >90%, did not inhibit the fibro-
nectin-cleaving or the elastolytic activity of cystic
fibrosis bronchial secretions.
Kinetics ofproteolysisofpurifiedfibronectin by
cysticfibrosis bronchial secretions, purifiedelastase,
and cathepsin G. To test further whether cathep-
sin G, other enzymes, or both contributed to the
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fibronectin-cleaving activity of cystic fibrosis bron-
chial secretions in addition to elastase, we examined
the time course and the kinetics of the breakdown
of purified fibronectin by these bronchial secretions
and compared the apparent molecular weights of
fibronectin breakdown products generated by these
three sources of enzymatic activity. The breakdown
pattern of fibronectin by a pool of cystic fibrosis
bronchial secretions is shown in figure 1, top, and
that of a mixture of purified elastase and cathepsin
G (3:1) is shown in figure 1, bottom, at 0, 1, 5, 10,
15, 30, and 60 min of incubation at 37 C. After 1
min of incubation with the cystic fibrosis bronchial
secretion the two monomers of fibronectin with ap-
parent molecular weights of 220 000 were split into
multiple fragments. The molecular weights of some
fragments were identical to those generated by
elastase and cathepsin G: 181000, 164000, 152000,
141 000, 138000, 108000, and 84000. Although ma-
jor breakdown products had similar molecular
weights, the time course of appearance was clearly
different in figure 1, top and bottom. These experi-
ments showed that (1)purified fibronectin was com-
pletely hydrolyzed by the cystic fibrosis bronchial
secretion as wellas by elastase and cathepsin G within
1 min and (2) although some breakdown products
of fibronectin generated by the cystic fibrosis bron-
chial secretion had molecular weights identical to
those generated by elastase and cathepsin G, the time
course of degradation and the molecular weights of
several fragments were different.
Zymographs. On the zymographs (figure 2)
copolymerized fibronectin appeared as dark stain-
ing. In figure 2 the first four lanes were loaded with
1.2 and 2.4 ug of fibronectin, lanes 5 and 6 with 3
~L of purified neutrophil elastase, lanes 7 and 8 with
a combination of 3 ~L of purified elastase and 1~L
of purified cathepsin G, lanes 9 and 10 with 1 ~L
of purified cathepsin G, and lanes 11 and 12 with
1~L of a pool of cystic fibrosis bronchial secretions.
Figure 2 shows an identically migrating, clear dou-
ble band for lanes 7 and 8 and lanes 11 and 12. The
results were identical for a pH of the incubation
buffer of 6.8, 7.4, and 8.3. Thus this experiment
demonstrated that the fibronectin-cleaving activity
of cystic fibrosis bronchial secretions comigrated
with purified elastase and cathepsin G. No other
zones of fibronectin cleavage were observed under
our experimental conditions. Control experiments
confirmed that the clear bands corresponded to
degradation of fibronectin by proteases. When the
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Figure 1. Top, proteolytic activity of I ul, of a pool of
cystic fibrosis bronchial secretions against purified fibro-
nectin after 0, 1,5, 10, IS, 30, and 60 min of incubation
at 37 C, The proteolysis of fibronectin was examined by
PAGE (running gel, 7,5l1Jo [wt/volJ) and subsequent im-
munoblotting. The molecular weights were monitored
using standard proteins (Biorad). Bottom, an identical ex-
periment, in which 3 ul, of purified elastase and I ul, of
purified cathepsin G were incubated with fibronectin. Ma-
jor fragments with molecular weights of 181000, 164000,
152000, 141000, 138000, 108000, and 84 000 appeared
after incubation of fibronectin with the bronchial secre-
tion (top) and with purified enzymes (bottom), but the
time course of appearance of fragments and the molecu-
lar weights of other fragment s were different. Lanes I,
2, 10, and II were loaded with 1.211g of purified fibronec-
tin (FN) .
bronchial secretion and the purified neutrophil en-
zymes were heated at 90 C for 15 min before elec-
trophoresis, no clear bands appeared. Degradation
of the rabbit antibody to fibronectin or the antibody
Figure 2. Zymograph in which the proteolytic effect of
I ul, of purified elastase (E; lanes 5 and 6), 3 ul, of puri-
fied elastase plus I ul, of purified cathepsin G (E + C;
fanes 7 and 8), I ul, of purified cathepsin G (C; fanes 9
and 10), and I ul, of a pool of cystic fibrosis (CF) bron-
chial secretions (lanes II and 12) on purified fibronectin
copolymerized in a polyacrylamide gel (7.5% [wt/voll)
was evaluated after electrophoresis of the unheated sam-
ples (40 C) through the gel. Purified fibronectin (1.2 or
2.4 I1g) was loaded on fanes 1-4. The two arrows point
to areas of proteolysis of fibronectin, which appear as clear
bands. The fibronectin-cleaving activity of cystic fibrosis
bronchial secretions comigrated with the combination of
elastase plus cathepsin G in a double band.
to rabbit IgG by enzymes transferred to the Novilon
membrane was excluded because the clear zones ap-
peared also when the Novilon membrane was treated
with 2 mM PMSF before incubation with the anti-
bodies.
Because free granulocyte elastase can be quanti-
tated in cystic fibrosis bronchial secretions by mea-
suring elastolytic activity, we measured the mean
elastolytic activities in these bronchial secretions in
relation to bacterial colonization (with and without
P. aeruginosa), age, and disease stage (table 3) to de-
termine precisely the amount of enzymes responsi-
ble for fibronectin-cleaving activity. Bronchial secre-
tions from patients with cysticfibrosis colonized with
P. aeruginosa had significantly higher mean elasto-
lytic activity than those from patients not colonized
with P. aeruginosa (P < .01), patients>17y old had
significantly higher mean elastolytic activities than
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Table 3. Elastolytic activity and protein concentration of cystic fibrosis bronchial secretions.
Suter et al.
No. of
Cystic fibrosis Bronchial Elastolytic Total protein
group Patients secretions activity (UE) concentration (giL)
All patients 24 194 1.61 ± 0.85 5.8 ± 3.8
P. aeruginosa
Colonized 15 111 1.82 ± 0.88* 5.7 ± 4.3
Not colonized 9 83 1.28 ± 0.72* 5.9 ± 3
Age (y)
17-21 9 44 2.14 ± 0.9t 6.8 ± 5.1
1\4-8Y3 10 54 1.23 ± 0.69t 4.5 ± 3.2
Disease stage
II 6 21 1.39 ± 0.6+ 5.2 ± 2.1
ll1 + IV 6 30 3.0 ±' 1.4+ 10.1 ± 4.6
NOTE. Elastolytic activity ismg of3H-labeled elastin solubilized (16 h at 37 C) by1 mL ofundiluted sample. Data aremean ± SO
values. The Mann-Whitney test was used for comparisons between groups.
* P < .01.
t P < .01.
+P <.01.
did those less than nine years old (P < .01), and bron-
chial secretions from patients who remained at dis-
ease stage II throughout the observation period had
significantly lower mean elastolytic activity than
those from patients with disease stages III and IV,
regardless of their bacterial colonization status (P
< .01). Two patients not colonized with P. aerugi-
nosa were in the group including disease stages III
and IV.
The mean ± SD elastolytic activity of the culture
supernatants of three elastase-producing strains of
P. aeruginosa was 1.2 ± 0.35 VE. Purified leuko-
cyte elastase had an elastolytic activity of 7.78 ± 0.59
VE, and the fibronectin-cleaving activity of 1 IJLof
purified elastase and cathepsin G was 33070 ± 4%
and 30% ± 3%, respectively.
Proteolysis ofcellularfibronectin by cysticfibro-
sis bronchial secretions. We used frozen sections
of lung tissue from an individual without cystic fibro-
sis to reveal cellular fibronectin on the surface of
mucosal cells before and after incubation of the tis-
sue with a cystic fibrosis bronchial secretion for I
min. The results of three separate experiments were
similar. Figure 3 shows the effect of the cystic fibro-
sis bronchial secretion of fibronectin of airway
mucosal cells. Figure 3A shows the lung tissue sec-
tion stained with hematoxylin and eosin. Immuno-
fluorescent fibronectin appears in figure 3B. After
incubation of the lung tissue section with a cystic
fibrosis bronchial secretion for 1 min, the immuno-
fluorescent fibronectin had disappeared (figure 3C).
When the cystic fibrosis bronchial secretion was
preincubated with an excess amount of Eglin C, in-
cubation of this secretion with the lung tissue had
no effect on tissue fibronectin fluorescence. A con-
trol experiment had shown that the bright immuno-
fluorescence observed before incubation with the cys-
tic fibrosis bronchial secretion could not be observed
when the FITC-conjugated antibody to fibronectin
was adsorbed with purified fibronectin before use.
Discussion
The results of our study show that bronchial secre-
tions from patients with cystic fibrosis and patients
with chronic bronchitis with acute exacerbations con-
tained large amounts of 1251-fibronectin-cleavingac-
tivity, whereas only small amounts were found in
saliva from patients with cystic fibrosis and normal
individuals (table 1). In contrast to the patients with
chronic bronchitis, in whom the 1251-fibronectin-
cleaving activity was present only during acute ex-
acerbations, fibronectin-cleaving activity was found
in all 194 samples of bronchial secretions from pa-
tients with cystic fibrosis who were followed up for
a period of 4.5 y.
The test that we developed for measuring fibro-
nectin-cleaving activity with 1251-fibronectin bound
to Sepharose beads as a substrate did not allow us
to quantitate the enzyme(s) involved precisely be-
cause the enzymatic reaction was not linear, regard-
less of the enzyme source tested (bronchial secretions
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Figure 3. A, hematoxylin and eosin
staining of a 4-~m-thick section of
deep-frozen lung tissue. Immunoflu-
orescent staining of fibronectin was
done on a similar section (B) before
and (C) after I min of incubation in
a moist chamber with 200 ILL of a cys-
tic fibrosis bronchial secretion. After
incubation, most of the immunofluo-
rescent fibronectin had disappeared.
or purified neutrophil elastase and cathepsin G). This
observation may be explained by the presence of sev-
eral cleavage sites on the fibronectin molecule, as
shown by the degradation pattern of unlabeled
fibronectin (figure 1). The time course of degrada-
tion of unlabeled fibronectin confirms the rapidity
of proteolysis of fibronectin and argues against the
hypothesis that the radioactively labeled fibronec-
tin was more susceptible to proteolysis because of
the labeling procedure. We therefore attempted first
to identify the enzymes responsible for fibronectin
cleavage by bronchial secretions. For this purpose
we used inhibitors and determined the degradation .
pattern of purified fibronectin by bronchial secre-
tions in comparison to purified elastase and cathep-
sin G, which were the enzymes most likely involved
in fibronectin cleavage [29, 34]. Finally, we used
zymographs [21, 22] to estimate the migration of
fibronectin-degrading enzymes in bronchial secre-
tions, in comparison to the migration of purified
elastase and cathepsin G.
The inhibition of 90070 and 87070 of 125I-fibronec-
tin-cleaving activity by PMSF and Eglin C, respec-
tively, showed that the enzymes involved were most
likely serine proteases, such as neutrophil elastase
and cathepsin G [24-26, 32, 33] (table 2). The two
inhibitors Ac-Ala-Ala-Pro-val-ClrCl, and Ac-Ala-
Pro-Phe-ChCI2, which are specific for neutrophil
elastase and cathepsin G, respectively, when used
with purified enzymes [26], did not allow us to dis-
tinguish further the enzymes involved in the 1251_
fibronectin-cleaving activity of cystic fibrosis
bronchial secretions because the inhibitors lost their
specificity at a concentration of I mM, as demon-
strated by inhibition of the activity of purified
elastase and cathepsin G (table 2). We observed this
problem with Eglin C [12], for which the concentra-
tions required for inhibiting the elastolytic activity
of cystic fibrosis bronchial secretions was much
higher than for an identical amount of elastolytic
activity of purified neutrophil elastase. These obser-
vations suggest that such specific inhibitors are not
always suitable tools for identifying enzymatic ac-
tivities within biologic fluids . In biologic fluids these
inhibitors may bind unspecifically to components
other than enzymes or to enzymes without activity
on the substrate tested. When we compared the time
course of degradation of purified fibronectin by cys-
tic fibrosis bronchial secretions and purified neutro-
phil elastase and cathepsin G (either alone or in com-
bination), we found that seven breakdown products
with identical molecular weights were generated by
cystic fibrosis bronchial secretions (figure 1,top) as
well as by the combination of elastase and cathep-
sin G (figure 1, bottom). Because human neutrophils
contain "-'3 ug of elastase for 1 ug of cathepsin G,
we used purified elastase and cathepsin G in a mix-
ture of 3:1 [33]. However, the time course of degra-
dation and the molecular weights of other fragments
were clearly different. This finding raises the ques-
tion of whether other enzymes, either from bacteria
or other endogenous protease(s), were involved in
the degradation of fibronectin or of its fragments
generated by neutrophil proteases in cystic fibrosis
bronchial secretions or whether this activity was
related to a different proportion of elastase/cathepsin
G in these bronchial secretions than the proportion
of 3:1 that was used for the purified enzymes. The
best evidence that neutrophil elastase and cathepsin
G were the main enzymes involved in fibronectin-
cleaving activity of cystic fibrosis bronchial secre-
tions is shown on the zymographs (figure 2). These
experiments showed that over a pH range of the in-
cubation buffer ranging from 6.8 to 8.3, fibronectin-
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cleaving activity of cystic fibrosis bronchial secre-
tions comigrated with the fibronectin-cleaving ac-
tivity of a mixture (3:1) of purified neutrophil
elastase and cathepsin G.
Taken together, these results suggest that neutro-
phil elastase and cathepsin G are both involved in
the fibronectin-cleaving activity of cystic fibrosis
bronchial secretions.
In the experiments described above we used
fibronectin purified from plasma [17]. Although
plasma and cellular fibronectins are very similar in
molecular properties (they have nearly identical
amino-acid compositions and secondary and tertiary
structures), cellular fibronectin, in contrast to plasma
fibronectin, is present not only in dimers but also
in multimers [8]. We therefore examined the effect
of cystic fibrosis bronchial secretions on microscopic
sections of lung tissue and especially of airway
mucosa by revealing cellular fibronectin before and
after incubation of the tissue with a cystic fibrosis
bronchial secretion. Figure 3 clearly shows a strik-
ing decrease of fibronectin fluorescence on the sur-
face of mucosal cells as well as of intercellular
fibronectin after exposure to the cystic fibrosis bron-
chial secretion. This experiment demonstrated that
cystic fibrosis bronchial secretions also had proteo-
lytic activity on cell-bound fibronectin.
We knew from previous studies [11-13] that bron-
chial secretions from patients with cystic fibrosis in-
fected with P. aeruginosa contained high amounts
of free neutrophil elastase (a mean of 55 ug/ml, of
sputum). In contrast to the kinetics of proteolysis
of 125I-fibronectin by the neutrophil enzymes elastase
and cathepsin G, the proteolytic degradation of 3H_
labeled elastin by these enzymes was linear over the
incubation period tested. To determine precisely the
amount of neutrophil elastase, we measured elasto-
lytic activity in bronchial secretions from patients
colonized with P. aeruginosa as well as patients not
colonized with this organism and compared free
elastolytic activity of these two groups, as well as
that of bronchial secretions of younger vs. older pa-
tients and patients with high vs. low disease stages
(table 3). Significantly higher elastolytic activity in
bronchial secretions was found in older vs. younger
patients, in patients with high vs. low disease stages,
and in those colonized with P. aeruginosa vs. the
patients colonized with other bacterial pathogens.
These values, however, represent elastolytic activity
per milliliter of sputum and do not reflect the total
elastase burden to which the airways of the patients
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wereexposed. As weshowed previously [12], the spu-
tum quantity and therefore the total elastase bur-
den decrease significantly after antimicrobial treat-
ment in patients with cystic fibrosis colonized with
P. aeruginosa. Becausethe kineticsof 125I-fibronectin
degradation were not comparable to those of 3H_
labeled elastin degradation, no correlation between
the enzymatic activitieson these two substrates could
be calculated.
Because in all these patients the 125I-fibronec-
tin-cleaving activity of saliva was much lower than
that of bronchial secretions, it is conceivable that
the fibronectin-cleaving activity from bronchial
secretions rather than from saliva led to degradation
of surface fibronectin of buccal epithelial cells. In-
deed, bronchial secretions reach the oropharynx dur-
ing coughing and during chest physiotherapy, and
because they contain high amounts of potent pro-
teolytic enzymes, they might contribute to the alter-
ation of epithelial surfaces of the upper respiratory
tract. An increase in elastase content in saliva of
postoperative patients was found to precede coloni-
zation with gram-negative bacilli [35]. The origin of
the elastase wasmost likely from neutrophils, accord-
ing to the inhibition experiments shown in this study,
but whether elastase was released by neutrophils
within the upper respiratory tract - for example, in
crevicular fluid - or whether it may have originated
from the lower respiratory tract was not clear.
Although the correlation between colonization
with gram-negative bacilli of the upper respiratory
tract and the absence of fibronectin on buccal epi-
thelial surfaces is well documented [7-10, 35], the
significance of the absence of surface fibronectin
from the lower-respiratory-tract epithelium as a fac-
tor favoring colonization with gram-negative bacte-
ria is unknown. Acid injury favors adherence of
mucoid and nonmucoid P. aeruginosa to tracheal
epithelium [36], but whether acid injury destroys
fibronectin on cell surfaces is not known. Although
we have shown that fibronectin was present on the
surface of epithelial cells of small airways of normal
human lung tissue and that surface fibronectin dis-
appeared after incubation of the tissue for I min with
cystic fibrosis bronchial secretions, the correlation
of adherence of P. aeruginosa to epithelial cell sur-
faces of the lower respiratory tract of patients with
cystic fibrosis and absence of surface fibronectin re-
mains to be established. That the proteolytic activity
of neutrophil elastase and cathepsin G is not limited
to fibronectin is certain: Elastase destroys the three
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major structural proteins of the lung and the airways,
which are elastin, collagen, and proteoglycans [37,
38]. Therefore, it is likely that these proteases pro-
duce extensive damage to airway epithelia. Other fac-
tors favoring colonization with P. aeruginosa of the
lower respiratory tract, such as adherence to mucins,
have been found [39], but the peculiar shift from
colonization with gram-positive to gram-negative
bacilli in patients with cystic fibrosis cannot be ex-
plained by this finding alone, unless the binding
properties of cystic fibrosis mucin also changed with
time. What does change with time is the elastase bur-
den to which the airways are continuously exposed
(table 3).
In summary, we have shown that bronchial secre-
tions, much more than saliva, from patients with cys-
tic fibrosis contain fibronectin-cleaving activity over
prolonged periods, in contrast to those from patients
with chronic bronchitis, in which fibronectin-cleav-
ing activity was present only during acute exacerba-
tions. This fibronectin-cleaving activity was mostly
due to neutrophil elastase and cathepsin G and was
shown to degrade surface fibronectin on epithelial
cells of small airways of normal lung tissue. Our
results suggest that fibronectin-cleaving activity of
bronchial secretions rather than saliva may favor the
colonization with P. aeruginosa of the upper respi-
ratory tract of patients with cystic fibrosis and that
the role of proteolytic activity on surface fibronec-
tin of the lower respiratory tract in the persistence
of colonization with P. aeruginosa should be further
studied. Prevention of colonization with P. aerugi-
nosaof the upper respiratory tract of patients with
cystic fibrosis could be attempted by using topical
elastase and cathepsin G inhibitors such as Eglin C
to protect surface fibronectin of buccal epithelial
cells, as was suggested for the prevention of coloni-
zation with gram-negative bacilli in postoperative pa-
tients [35]. If the adherence of P. aeruginosa to epi-
thelial cell surfaces of the lower respiratory tract is
mediated by a similar mechanism, systemic rather
than local treatment with protease inhibitors would
be required. No synthetic inhibitor of neutrophil
elastase and cathepsin G is currently available for
clinical studies. To our knowledge, only one ther-
apeutic approach was shown to decrease the fre-
quency of colonization with P. aeruginosa of the re-
spiratory tract of patients with cystic fibrosis: In a
placebo-controlled study, patients with cystic fibro-
sis receivingalternate-day prednisone treatment were
less often colonized with P. aeruginosa [40]. The
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anti-inflammatory effect of prednisone may haveled
to a decrease of migration of neutrophils into the
respiratory tract, with a concomitant decrease of the
protease burden originating from neutrophils within
the airways. Webelieve that compounds that poten-
tially lead to a decrease of the protease burden in
the airways of patients with cystic fibrosis should be
evaluated in clinical studies.
References
I. Pennington JE, Wolff SM, Puziss M. Summary of a work-
shop on infections in patients with cystic fibrosis. J Infect
Dis 1979;140:252-6
2. Marks MI. The pathogeneis and treatment of pulmonary
infections in patients with cystic fibrosis. J Pediatr 1981;
98:173-9
3. Pier GB. Pulmonary disease associated with Pseudomonas
aeruginosa in cystic fibrosis: current status of host-bacte-
rium interaction. J Infect Dis 1985;151:575-80
4. Bruce MC, Poncz L, Klinger JD, Stern RC, Tomashefski JF
Jr, Dearborn DG. Biochemical and pathologic evidence
for proteolytic destruction of lung connective tissue in cystic
fibrosis. Am Rev Respir Dis 1985;132:529-35
5. Sobonya RE, TaussigLM. Quantitative aspects of lung pathol-
ogy in cystic fibrosis. Am Rev Respir Dis 1986;134:290-5
6. Wheeler WB, Williams M, Matthews W,Colten HR. Progres-
sion of cystic fibrosis lung disease as a function of serum
immunoglobulin G levels: a 5-year longitudinal study. J
Pediatr 1984;104:695-9
7. Woods DE, Straus DC, Johanson WG, Bass JA. Role of
fibronectin in the prevention of adherence of Pseudomo-
nasaeruginosa to buccal cells. J Infect Dis 1981;143:784-90
8. Abraham SN, Beachey EH, Simpson WA. Adherence of
Streptococcus pyogenes, Escherichia coliand Pseudomo-
nas aeruginosa to fibronectin-coated and uncoated epi-
thelial cells. Infect Immun 1983;41:1261-8
9. Woods DE, Bass JA, Johanson WG, Straus DC. Role of ad-
herence in the pathogenesis of Pseudomonas aeruginosa
lung infection in cystic fibrosis patients. Infect Immun
1980;30:694-9
10. Woods DE, Straus DC, Johanson WG, Bass JA. Role of sal-
ivary protease activity in adherence of gram-negative bacilli
to mammalian buccal epithelial cells in vivo. J Clin Invest
1981;68:1435-40
11. Suter S, Schaad VB, Roux L, Nydegger VE, Waldvogel FA.
Granulocyte neutral proteases and pseudomonas elastase
as possible causes of airway damage in patients with cys-
tic fibrosis. J Infect Dis 1984;149:523-31
12. Suter S, Schaad VB, Tegner H, Ohlsson K, Desgrandchamps
0, Waldvogel FA. Levels of free granulocyte elastase in
bronchial secretions from patients with cystic fibrosis: ef-
fect of antimicrobial treatment against Pseudomonas aeru-
ginosa. J Infect Dis 1986;153:902-9
13. Goldstein W, Doring G. Lysosomal enzymes from polymor-
phonuclear leukocytes and proteinase inhibitors in patients
with cystic fibrosis. Am Rev Respir Dis 1986;134:49-56
14. Kraemer R, Riideberg A, Klay M, Rossi E. Relationship be-
tween clinical conditions, radiographic findings and pul-
100
monary functions in patients with cystic fibrosis. Helv
Paediatr Acta 1979;34:417-28
15. Chrispin AR, Norman AP. The systematic evaluation of the
chest radiograph in cystic fibrosis. Pediatr Radiol 1974;
2:101-6
16. Washington JA. Laboratory procedures in clinical micro-
biology. New York: Springer-Verlag, 1981
17. Morgenthaler JJ. Hydrophobic chromatography of fibronec-
tin. FEBS Lett 1982;150:81-4
18. McConahey PJ, Dixon FJ. A method of trace iodination of
proteins for immunological studies. Int Arch Allergy Appl
Immunol 1966;29:185-9
19. Laemmli UK. Cleavage of structural proteins during the as-
sembly of the head of bacteriophage T4. Nature 1970;
227:680-5
20. Gershoni JM, Palade GE. Protein blotting: principles and
applications. Anal Biochem 1983;131:1-15
21. Heussen C, Dowdle EB. Electrophoretic analysis of plasmino-
gen activators in polyacrylamide gels containing sodium
dodecyl sulfate and copolymerized substrates. Anal Bio-
chern 1980;10.2:196-202
22. Chen J-M, Chen W-T. Fibronectin-degrading proteases from
the membranes of transformed cells. Cell 1987;48:193-203
23. Hornebeck W, Schnebli HP. Effect of different elastase
inhibitors on leukocyte elastase preadsorbed to elastin.
Hoppe Seylers Z Physiol Chern 1982;363:455-8
24. Baugh RJ, Travis J. Human leukocyte granule elastase: rapid
isolation and characterization. Biochemistry 1976;15:
836-41
25. Feinstein G, Janoff A. A rapid method for purification of
human granulocyte cationic neutral proteases: purification
and characterization of human granulocyte chymotrypsin-
like enzyme. Biochim Biophys Acta 1975;403:477-92
26. Nakajima K, Powers JC, Ashe BM, Zimmerman M. Map-
ping the extended substrate binding site of cathepsin G
and human leukocyte elastase. Studies with peptide sub-
strates related to the ell-protease inhibitor reactive site. J
Bioi Chern 1979;254:4027-32
27. Rink H, Liersch M, Sieber P, Meyer F. A large fragment ap-
proach to DNA synthesis: total synthesis of a gene for the
protease inhibitor Eglin C from the leech Hirudo medici-
nalis and its expression in E. coli. Nucleic Acid Res
1984;12:6369-87
28. Hudgin RL, Charleson SE, Zimmerman M, Mumford R,
Suter et al.
Wood PL. Enkephalinases: selectivepeptide inhibitors. Life
Sci 1981;29:2593-601
29. Yamada KM. Biochemistry of fibronectin. In: Horowitz MI,
ed. The glycoconjugates. Vol. 3. New York: Academic Press,
1983:331-62
30. Hudson L, Hay FC. Practical immunology. Oxford: Black-
well Scientific Publications, 1976
31. Zardi L, Siri A, Carnemolla B, Cosulich E, Viale G, Santi
L. A simplified procedure for the preparation of antibod-
ies to serum fibronectin. J Immunol Methods 1980;34:
155-65
32. Schmidt W, Havemann K. Chymotrypsin-like neutral pro-
teases from Iysosomes of human polymorphonuclear leu-
kocytes. In: Havemann K, Janoff A, eds. Neutral proteases
of human polymorphonuclear leukocytes. Baltimore: Ur-
ban and Schwarzenberg, 1978:150-60
33. Schmidt W. Neutrale Proteasen aus menschlichen Leukozyten:
Isolierung, Charakterisierung und biologische Wirkungen.
Inaugural-dissertation, Marburg, Federal Republic of Ger-
many: University of Marburg, 1975
34. McDonald JA, Baum BJ, Rosenberg DM, Kelman JA, Brin
SC, Crystal RG. Destruction of a major extracellular adhe-
siveglycoprotein (fibronectin) of human fibroblasts by neu-
tral proteases from polymorphonuclear leukocyte granules.
Lab Invest 1979;40:350-7
35. Dal Nogare AR, Toews GB, Pierce AK. Increased salivary
elastase precedes gram-negative bacillary colonization in
post-operative patients. Am Rev Respir Dis 1987;135:671-5
36. Ramphal R, Pyle M. Adherence of mucoid and non-mucoid
Pseudomonas aeruginosa to acid-injured tracheal epithe-
lium. Infect Immun 1983;41:345-51
37. Gadek JE, Fells GA, Zimmerman RL, Rennard SI, Crystal
RG. Antielastases of the human alveolar structures. Im-
plications for the protease-antiprotease theory of emphy-
sema. J Clin Invest 1981;68:889-98
38. Sandberg LB, Soskel NT, Leslie JG. Elastin structure, bio-
synthesis, and relation to disease states. N Engl J Med
1981;304:566-79
39. Ramphal R, Pyle M. Evidence for mucins and sialic acid as
receptors for Pseudomonas aeruginosa in the lower respi-
ratory tract. Infect Immun 1983;41:339-44
40. Auerbach HS, Kirkpatrick JA, Williams M, Colten HR.
Alternate-day prednisone reduces morbidity and improves
pulmonary function in cystic fibrosis. Lancet 1985;2:686-8
